ScreenerHero

LBRX LB Pharmaceuticals Inc

NAS · US · Healthcare · Biotechnology · lbpharma.us
34.16USD-0.29%Mkt Cap: 1.10B $P/E: 341.60

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small mole…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
HeadlineSourceTime
Older
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?

LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.

Investor's Business Daily
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment

LB Pharmaceuticals (LBRX) has drawn fresh investor attention after appointing Joseph M. Miller as Chief Financial Officer. The announcement coincides with preparations for NOVA-2 trial readouts and a potential LB-102 launch in schizophrenia. Despite a pullback over the last day with a 1-day share price return of down 3.96% to US$47.52, LB Pharmaceuticals has delivered a 66.56% 90-day share price return and a 132.49% year-to-date share price return, which suggests that momentum has been...

Simply Wall St.
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls

Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls

The Fly